HVIVO launches unified brand identity

hVIVO launches unified brand identity reflecting strategic transformation into integrated clinical development partner

Reinforces establishment of purpose-built, fully integrated platform, designed to accelerate pathway to clinical proof-of-concept

London, UK - 14 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, today announces the launch of a new brand identity, reflecting the Group's strategic transformation from specialist provider to a differentiated end-to-end drug development partner.

The rebrand follows the successful integration of Venn Life Sciences, CRS and Cryostore and marks the completion of the Group's transition from a specialist services provider to a fully integrated platform supporting clients from preclinical strategy through to Phase II and selected Phase III programmes. All operating companies will now trade under the hVIVO brand, simplifying the Group's structure and re-enforcing its single partner model. This provides clients with one integrated team, clear continuity across the development pathway.

The Group now operates through four integrated service lines, forming a purpose-built platform designed to generate faster, more decisive, high-quality human data, reducing complexity, minimising handoffs and enabling novel, more efficient trial designs:

• Consulting: provides early stage scientific, regulatory and development strategy support across the drug development lifecycle, enabling clients to design robust programmes and generate decision ready data from the outset. Drawing on deep expertise in early drug development, clinical pharmacology and biostatistics, teams support sponsors from pre-clinical planning through to clinical proof-of-concept, including study design, dose rationale and regulatory strategy;
• Clinical Trials: provides specialist early phase clinical trial services through owned and controlled clinical research sites, supporting studies from First-in-Human through to Phase II and selected Phase III programmes. It includes full Phase I and II CRO services, complemented by Phase II and III site services delivered within hVIVO's facilities. This model enables greater operational control, accelerates timelines and ensures reliable recruitment across healthy volunteers, patient populations and specialist cohorts;
• Human Challenge Trials: enables rapid and controlled evaluation of vaccines and therapeutics by exposing healthy volunteers to well characterised pathogens under carefully controlled conditions. These studies allow earlier assessment of efficacy, biological response and dose selection compared to traditional field-based studies;
• Laboratories: provide specialist virology, immunology and biomarker analysis to support early phase clinical development, human challenge trials and standalone laboratory programmes. Closely integrated with clinical operations, services include assay development, sample analysis and data interpretation and biobanking with long-term storage capabilities.

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "This rebrand reflects our strategic transformation into a purpose-built, full-service international clinical development partner, addressing the industry's need for faster, high-quality data that can de-risk drug development.

"By bringing together consulting, clinical trials, human challenge trials and laboratories into a single, unified platform, we offer clients a seamless pathway from pre-clinical strategy to clinical proof-of-concept, delivered by one expert partner. Our unified brand reinforces the strength of our integrated model, proprietary infrastructure and deep scientific expertise, and our ability to ultimately help pharmaceutical and biotech companies bring important medicines to patients faster."

Anthony Farrell, Niall Gilchrist